Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial

التفاصيل البيبلوغرافية
العنوان: Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial
المؤلفون: G. Rastrelli, S. Cipriani, F. Lotti, I. Cellai, P. Comeglio, S. Filippi, V. Boddi, P. A. Della Camera, R. Santi, L. Boni, G. Nesi, S. Serni, M. Gacci, M. Maggi, L. Vignozzi
المصدر: Journal of Endocrinological Investigation. 45:1413-1425
بيانات النشر: Springer Science and Business Media LLC, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Endocrinology, Endocrinology, Diabetes and Metabolism
الوصف: Purpose Benign Prostatic Hyperplasia (BPH) is a result of prostate inflammation, frequently occurring in metabolic syndrome (MetS). Low testosterone is common in MetS. A randomized clinical trial was designed to evaluate if 24 weeks of testosterone therapy (TTh) in BPH men with MetS and low testosterone improve urinary symptoms and prostate inflammation. Methods One-hundred-twenty men with MetS waitlisted for BPH surgery were enrolled. They were categorized into normal testosterone (TT ≥ 12 nmol/L and cFT ≥ 225 pmol/L; n = 48) and testosterone deficient (TD) (TT n = 72) then randomized to testosterone gel 2% (5 g/daily) or placebo for 24 weeks. At baseline and follow-up, questionnaires for urinary symptoms and trans-rectal ultrasound were performed. Prostate tissue was collected for molecular and histopathological analyses. Results No differences in the improvement of urinary symptoms were found between TTh and placebo (OR [95% CI] 0.96 [0.39; 2.37]). In TD + TTh, increase in prostate but not adenoma volume was observed (2.64 mL [0.07; 5.20] and 1.82 mL [− 0.46; 0.41], respectively). Ultrasound markers of inflammation were improved. In a subset of 61 men, a hyper-expression of several pro-inflammatory genes was found in TD + placebo when compared with normal testosterone. TTh was able to counteract this effect. For 80 men, the inflammatory infiltrate was higher in TD + placebo than in normal testosterone (0.8 points [0.2; 1.4]) and TD + TTh men (0.9 points [0.2; 1.5]). Conclusions Twenty-four weeks of TTh in TD men with BPH and MetS improves ultrasound, molecular and histological proxies of prostate inflammation. This does not result in symptom improvement.
تدمد: 1720-8386
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::16e0004793f12f67069699f915744d87
https://doi.org/10.1007/s40618-022-01776-9
حقوق: OPEN
رقم الأكسشن: edsair.doi...........16e0004793f12f67069699f915744d87
قاعدة البيانات: OpenAIRE